Incyte’s Phase 3 TRuE-PN trials show ruxolitinib cream improves itch relief in prurigo nodularis, though TRuE-PN2’s primary endpoint fell short.
Latest Ratings for INCY
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 2022 | SVB Leerink | Downgrades | Market Perform | Underperform |
| Feb 2022 | Morgan Stanley | Maintains | Equal-Weight | |
| Jan 2022 | RBC Capital | Upgrades | Sector Perform | Outperform |
